STEALTH BIOTHERAPEUTICS CORP (MITO) Stock Price, Forecast & Analysis
NASDAQ:MITO • US85789A1051
MITO Key Statistics, Chart & Performance
The current stock price of MITO is 0.32 USD. In the past month the price increased by 0.95%. In the past year, price decreased by -65.96%.
MITO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MITO. When comparing the yearly performance of all stocks, MITO is a bad performer in the overall market: 78.6% of all stocks are doing better.
MITO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MITO. MITO has a bad profitability rating. Also its financial health evaluation is rather negative.
MITO Financial Highlights
Over the last trailing twelve months MITO reported a non-GAAP Earnings per Share(EPS) of -0.08.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.5% | ||
| ROE | N/A | ||
| Debt/Equity | -0.26 |
MITO Forecast & Estimates
7 analysts have analysed MITO and the average price target is 1.81 USD. This implies a price increase of 465.78% is expected in the next year compared to the current price of 0.32.
MITO Ownership
MITO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 402.079B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.85 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MITO
Company Profile
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company is headquartered in George Town, Grand Cayman and currently employs 38 full-time employees. The company went IPO on 2019-02-15. The firm is focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, a structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. This mechanism of action has shown potential clinical benefit in both rare genetic and common age-related ophthalmic and cardiac diseases entailing mitochondrial dysfunction. The firm's second clinical product candidate include SBT-272, for rare neurological diseases involving mitochondrial dysfunction, with a preliminary focus on amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Its clinical product candidate also includes SBT-550 series for rare neurological indications, including Friedreich’s ataxia (FRDA).
Company Info
STEALTH BIOTHERAPEUTICS CORP
190 Elgin Avenue, George Town
GEORGE TOWN GRAND CAYMAN KY1-9005 KY
CEO: Irene (Reenie) McCarthy
Employees: 38
Phone: 6176006888.0
STEALTH BIOTHERAPEUTICS CORP / MITO FAQ
What does MITO do?
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company is headquartered in George Town, Grand Cayman and currently employs 38 full-time employees. The company went IPO on 2019-02-15. The firm is focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, a structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. This mechanism of action has shown potential clinical benefit in both rare genetic and common age-related ophthalmic and cardiac diseases entailing mitochondrial dysfunction. The firm's second clinical product candidate include SBT-272, for rare neurological diseases involving mitochondrial dysfunction, with a preliminary focus on amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Its clinical product candidate also includes SBT-550 series for rare neurological indications, including Friedreich’s ataxia (FRDA).
What is the current price of MITO stock?
The current stock price of MITO is 0.32 USD. The price decreased by -1.36% in the last trading session.
Does MITO stock pay dividends?
MITO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MITO stock?
MITO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does STEALTH BIOTHERAPEUTICS CORP belong to?
STEALTH BIOTHERAPEUTICS CORP (MITO) operates in the Health Care sector and the Biotechnology industry.